Neurovive (NEVPF) 5.2300 $NEVPF Global Ischemic Stroke

New Post Public Reply Private Reply Replies (0) Message Board

May 18, 2015 at 9:26 AM

Neurovive (NEVPF) 5.2300 $NEVPF

Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 391.24 (-3.11), ACOR: 30.04 (+0.14), GSK: 44.56 (-0.21), AZN: 68.66 (-0.63), ATHX: 1.27 (-0.01), CUR: 1.70 (-0.04)

NeuroVive Pharmaceutical: NeuroVive Completes Share Issue Raising SEK 70 Million for the Preparation of CicloMulsion(R)'s Clinical Trial in the US and Commercialization in Europe
Business Wire - Fri May 08, 1:33AM CDT
Regulatory News:

NeuroVive Announces the Intention to Raise Additional Capital Through a Private Placement
Business Wire - Thu May 07, 10:50AM CDT
Regulatory News:

Neurovive Pharmaceutical: FIrst Patient Enrolled in Clinical Phase II Study for Kidney Protection During Heart Surgery
Business Wire - Mon Apr 27, 1:47AM CDT
Regulatory News:

Neurovive Pharmaceutical: Clinical Phase II Study with NeuroSTAT(R) for Traumatic Brain Injury Passes Safety Evaluation
Business Wire - Tue Apr 21, 3:06AM CDT
Regulatory News:

Neurovive Pharmaceutical: NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL
Business Wire - Mon Apr 20, 1:41AM CDT
Regulatory News:

NeuroVive Pharmaceutical: Development of NVP014 for the Treatment of Stroke Enters New Phase in Collaboration with Isomerase Therapeutics
Business Wire - Fri Apr 17, 1:40AM CDT
Regulatory News:

NeuroVive Pharmaceutical reports change in number of shares and votes
M2 - Wed Apr 01, 3:08AM CDT
NeuroVive Pharmaceutical AB (STO:NVP), the mitochondrial medicine company, announced on Tuesday that the number of shares and votes of the company, registered with the Swedish Companies Registration Office, has increased by 1,300,000.

Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 56.75 (unch), MRK: 60.21 (-0.02), QGEN: 24.64 (-0.07), CBMG: 27.50 (-1.31)

OnCore Biopharma and Tekmira Pharmaceuticals Files for Merger - Releases Further Details about License Agreement With NeuroVive
Business Wire - Thu Feb 05, 2:28AM CST
Regulatory News:
TKMR: 13.94 (+0.09)

Neurovive Pharmaceutical: NeuroVive and Skane University Hospital Initiate Collaboration on Clinical Phase II Study on Kidney Protection During Heart Surgery
Business Wire - Tue Dec 02, 1:40AM CST
Regulatory News:

NeuroVive reduces loss in third quarter 2014
M2 - Thu Nov 20, 4:57AM CST
NeuroVive Pharmaceutical AB (STO:NVP) on Wednesday reported loss before tax of SEK3,761,000, or diluted loss per share of SEK0.18, for the third quarter of 2014, from 1 July 2014 to 30 September 2014.

Global Reperfusion Injury Therapeutic Pipeline Review, H1 2014 - 7 Companies & 15 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ffkhq3/reperfusion) has announced the addition of the "Reperfusion Injury - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Reperfusion Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reperfusion Injury and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - NeuroVive Pharmaceutical AB - Scynexis, Inc. - Apeptico Forschung und Entwicklung GmbH - Stealth Peptides Inc. - Eustralis Pharmaceuticals Ltd - Nyken BV - Vasade Biosciences, Inc. Drug Profiles - cyclosporine - MTP-131 - GNX-5086 - bucillamine - Recombinant Protein to Inhibit CXCL for Cardiovascular and CNS Disorders - EUC-002 - AP-301 - NYK-1112 - Type 5 Adenylyl Cyclase Inhibitors - Small Molecule for Reperfusion Injury - MitoSNO - PVIIA - RIIIK - Small Molecules to Inhibit Cyclophilin D for Ischemia Reperfusion Injury, Neurodegenerative Diseases, And Trauma - Synthetic Peptides to Activate Complement C3 for Immunology, Cardiovascular and CNS Disorders For more information visit http://www.researchandmarkets.com/research/ff...eperfusion

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ZKH and Intel Launch Industrial AI Model at the Edge

Industrial Revolution at the Edge Forget the horseless carriage; this time, we're talking about AI stepping onto the factory floor in China. ZKH Group Limited has spun a new yarn in MRO with its AI subsidiary, LingLong Intelligence, partnering up with tech giant Intel to launch the LingLong Insight 1.0. The venue was Intel Connection 2026 in Suzhou, China, where this...

Hudsonville's Leadership Shift Eyes the Future

Hudsonville's New Chapter: Enter CJ Ellens When a firm as storied as Hudsonville Ice Cream elects a new captain at the helm, folks sit up and take notice. CJ Ellens, already well-embedded in the fabric of Hudsonville, is set to steer the ship starting January 1, 2027. This isn't just a revolving door of C-suites, but more like a passing of the torch to someone bred in the...

Endeavor & GoPath's Game-Changing Cancer Test Launch

Breaking Ground in Prostate Cancer Testing Just when you thought the medical field couldn't shake things up further, Endeavor Health and GoPath Diagnostics swoop in with a new genetic test for prostate cancer. This ain't just any run-of-the-mill test—it's the first of its kind to hit the clinical scene. The focus here is on sorting out which men with prostate cancer are...

PRA Group Marks 30 Years with Nasdaq Bell Ringing

A Milestone in Times Square Thirty trips around the sun, and here we are: PRA Group, the change-maker in the world of nonperforming loans, is celebrating by ringing the Nasdaq Opening Bell. It's a pretty big to-do in the financial world to get this nod, standing out in New York City's Times Square, no less. This shindig showcased Martin Sjolund, their President and CEO,...

Latitude Expands Food Allergy Care to Long Island

New Clinic Brings Specialized Care to Long Island Listen, when it comes to healthcare, especially something as life-altering as food allergies, you're not just looking for any run-of-the-mill clinic. You're looking for the right place with the right people who get it. And folks in Long Island are getting something worth celebrating—a new clinic from Latitude Food...

Potomac Edison Targets Virginia Grid Revamp by 2030

Strengthening the Backbone of Virginia's Power Supply Ever had your lights flicker on a windy day and wondered if the power grid would hold? Potomac Edison, under the banner of FirstEnergy Corp., is stepping up with a game plan to fortify the electric spine of Virginia and its neighbors. They're diving into a multi-state adventure, rebuilding and erecting 138 kV...

Bird-X Welcomes Doolittle to Elevate Sales Strategy

Change in Flight: Bird-X Eyes Strategic Growth Well, here's one that might spread its wings wide. Emanuel Doolittle has joined Bird-X, Inc. as Director of Sales and Business Development. Now, let's not beat around the bush — Bird-X isn't a name you'd see thrown around daily stock talks, but it's stirring up interest in the pest control sector without question. Why...

Tripo AI's New Canvas Redefines 3D Workflow Process

Rethinking 3D Content Creation Well, well, well, Tripo AI is shaking things up in the 3D world with its new Agentic Canvas. This isn't just another gizmo to throw in the digital drawer; it's a tool looking to flip the whole 3D game on its head. Picture taking complex 3D workflows and molding them like clay into something that’s efficient and scalable. That’s what...

Tim Brewer Leads AXA XL's Growth in Commercial Bonds

AXA XL Welcomes a New Leader You know, insurance isn't exactly what sets hearts racing, but there's something intriguing about the chess game of leadership changes. AXA XL's latest move? They’ve roped in Tim Brewer to helm their Commercial Bonds for the Americas. A hefty role, sure, but one that comes with its fair share of high-stakes pressure. Kind of like betting on...

DriveNets' Big Role at FYUZ 26: AI Fabrics Spotlighted

Networking Titans Gather at FYUZ 26 Alright, folks, mark the first week of November as a field day for telecom and AI networking enthusiasts. DriveNets, a seasoned player in large-scale networking, is joining forces with some of the industry's giants—AT&T, KDDI, and Broadcom—at the Telecom Infra Project's flagship event, FYUZ 26, unfolding at The Westin Seattle. From...